CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>85% Organs [clinicaltrials:NCT02435732]

Bio2RDF identifier

NCT02435732

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02435732

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02435732

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

72

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02435732 arm group 1a80bba3a9250ea6628cb15a33d663a8 [clinicaltrials_resource:NCT02435732/arm-group/1a80bba3a9250ea6628cb15a33d663a8]

NCT02435732 arm group a2b2258ad68f1210822e0bff98b8d82a [clinicaltrials_resource:NCT02435732/arm-group/a2b2258ad68f1210822e0bff98b8d82a]

NCT02435732 arm group ba878abbdc7cbf2642eb162de05aeaa0 [clinicaltrials_resource:NCT02435732/arm-group/ba878abbdc7cbf2642eb162de05aeaa0]

NCT02435732 arm group d628e7dbad2dab5854d3faf699205e89 [clinicaltrials_resource:NCT02435732/arm-group/d628e7dbad2dab5854d3faf699205e89]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

Limiting brain death-in ...... Index (KDPI) over 85%.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>85% Organs

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement in brain death donors with KDPI over 85%, with the purpose of reducing the incidence of delayed graft function. over a 12 month period [clinicaltrials_resource:f0951e13396cb185d4c922d6c39e0d3b]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement in brain death donors with KDPI over 85%, with the purpose of reducing the incidence of delayed graft function. over a 12 month period [clinicaltrials_resource:75bac488f3d6dbf9407295af6da64e5c]

Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement in brain death donors with KDPI over 85%, with the purpose of reducing the incidence of delayed graft function. over a 12 month period [clinicaltrials_resource:94b57a553442fc441e5508d503ab343a]

Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement in brain death donors with KDPI over 85%, with the purpose of reducing the incidence of delayed graft function. over a 12 month period [clinicaltrials_resource:a18f32669390fbfb8f500bf13f3093f3]

Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement in brain death donors with KDPI over 85%, with the purpose of reducing the incidence of delayed graft function. over a 12 month period [clinicaltrials_resource:d76048bf981b937fe4b835e79052f471]

Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement in brain death donors with KDPI over 85%, with the purpose of reducing the incidence of delayed graft function. over a 12 month period [clinicaltrials_resource:dd33578a420dbd564e1054e9182abeb0]

collaborator [clinicaltrials_vocabulary:collaborator]

University of Wisconsin, Madison [clinicaltrials_resource:02047e0096c92af4a69eaa4490fe8a82]

completion date [clinicaltrials_vocabulary:completion-date]

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

This is a randomized, s ...... C1INH was used alone.)

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02435732 [clinicaltrials_resource:30f9c2c4a516267691ade582ba6e1951]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2015-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Placebo saline solution [clinicaltrials_resource:3e9f7ecd7aa646d16d9587df7f865a7b]

Heparin [clinicaltrials_resource:65e68e1739702f701134d4930591cd48]

CINRYZE [clinicaltrials_resource:ed910738f492b4878b91326650929a3b]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Complement C1 Inhibitor Protein [clinicaltrials_resource:0a6c46f344a30ebb9b7dedb6b8c3f0b7]

Calcium heparin [clinicaltrials_resource:4fe5c6162dd417c25b1c3553982f299d]

Heparin [clinicaltrials_resource:a04fdc71806f5f193a5cf838653becb4]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

No

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

University of Wisconsin, Madison [clinicaltrials_resource:02047e0096c92af4a69eaa4490fe8a82]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02435732

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

4

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase I, Single Center, Rand ...... or Risk Index (KDRI) Above 85%

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2015-0195

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Luis Fernandez, MD [clinicaltrials_resource:32473176c0eec3de4919be26983cf36f]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Luis Fernandez, MD [clinicaltrials_resource:06eca579a7728768b7a2bd9b8c192477]

overall official [clinicaltrials_vocabulary:overall-official]

Luis Fernandez, MD [clinicaltrials_resource:f39b66acbdbff4ff8582bc0583cb4d81]

overall status [clinicaltrials_vocabulary:overall-status]

Not yet recruiting [clinicaltrials_resource:39d12730c49ea76e1575ff9ca65c262b]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

University of Wisconsin, Madison [clinicaltrials_resource:02047e0096c92af4a69eaa4490fe8a82]

start date [clinicaltrials_vocabulary:start-date]

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02435732 study design [clinicaltrials_resource:0226c3f6aa5707c0dd3c5d614c1cf92f]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02435732

verification date [clinicaltrials_vocabulary:verification-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02435732

http://www.w3.org/2001/XMLSchema#string

title

CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>85% Organs

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

CINRYZE as a Donor Pre-treatme ...... s [clinicaltrials:NCT02435732]

@en